Your browser doesn't support javascript.
loading
Insights into LINE-1 reverse transcription guide therapy development.
Zehrbach, Nicholas M; Oh, Nakyung; Ishak, Charles A.
Afiliación
  • Zehrbach NM; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Oh N; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ishak CA; Department of Epigenetics and Molecular Carcinogenesis, University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Gynecologic Oncology and Reproductive Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: caishak@mdanderson.org.
Trends Cancer ; 10(4): 286-288, 2024 Apr.
Article en En | MEDLINE | ID: mdl-38499453
ABSTRACT
Subsets of long interspersed nuclear element 1 (LINE-1) retrotransposons can 'retrotranspose' throughout the human genome at a cost to host cell fitness, as observed in some cancers. Pharmacological inhibition of LINE-1 retrotransposition requires a comprehensive understanding of the LINE-1 ORF2p reverse transcriptase. Two recent publications, by Thawani et al. and Baldwin et al., report structures of LINE-1 ORF2p and address long-standing mechanistic gaps regarding LINE-1 retrotransposition. Both studies will be critical to design new specific inhibitors of the LINE-1 ORF2p reverse transcriptase.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Elementos de Nucleótido Esparcido Largo / Transcripción Reversa Límite: Humans Idioma: En Revista: Trends Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Elementos de Nucleótido Esparcido Largo / Transcripción Reversa Límite: Humans Idioma: En Revista: Trends Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos